Alvameline
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 3-(2-ethyltetrazol-5-yl)-1-methyl-5,6-dihydro-2H-pyridine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 120241-31-8 |
| ATC code | None |
| PubChem | CID 178030 |
| ChemSpider | 154980  |
| UNII | 4XFD7B36M6 |
| ChEMBL | CHEMBL131428 |
| Chemical data | |
| Formula | C9H15N5 |
| Mol. mass | 193.25 g/mol |
|
|
|
|
 (what is this?) (verify) |
|
Alvameline (Lu 25-109) is a M1 receptor agonist and M2/M3 receptor antagonist[1] that was under investigation for the treatment of Alzheimer's disease, but produced poor results in clinical trials[2] and was subsequently discontinued.
References
- ^ Sánchez C, Arnt J, Didriksen M, Dragsted N, Moltzen Lenz S, Matz J (June 1998). "In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro". Psychopharmacology 137 (3): 233–40. doi:10.1007/s002130050615. PMID 9683000.
- ^ Sramek JJ, Forrest M, Mengel H, Jhee SS, Hourani J, Cutler NR (1998). "A bridging study of LU 25-109 in patients with probable Alzheimer's disease". Life Sciences 62 (3): 195–202. doi:10.1016/S0024-3205(97)01087-4. PMID 9488097.
|
|||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
